NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
February 10, 2004 • Volume 1 / Number 6 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Notes

NCI Appoints New Deputy Director
Dr. Mark Clanton, former president-elect of the American Cancer Society, has been named deputy director for Cancer Care and Delivery Systems at NCI. Dr. Clanton received his M.D. from Tulane University Medical School and his M.P.H. in Health Policy and Management from the Harvard School of Public Health; he also holds a certificate in finance from the Cox School of Business at Southern Methodist University and is a graduate of Howard University. He is a fellow of the American Academy of Pediatrics. With 10 years of experience with managed care and health plan administration, he was the first African American to be promoted to the post of Chief Medical Officer of Blue Cross and Blue Shield of Texas. At Blue Cross, he was the executive responsible for new medical technology assessment, medical policy development, health services research, and leading the pharmacy drug program for more than 1 million members.

3,000 Patients Accrued to Cancer Trials Support Unit
Recently, NCI's Cancer Trials Support Unit (CTSU) achieved a significant milestone when it enrolled its 3,000th patient on a clinical trial. CTSU was created to make NCI-supported Cooperative Group treatment trials more accessible to qualified oncologists and their patients. It also has helped coordinate the multiple Cooperative Group regulatory systems, thereby helping to reduce the administrative burden on physicians participating in these large, multicenter trials. Since opening in October 2000, CTSU now offers a menu of 49 protocols across a variety of common solid tumors and hematologic cancers. Investigators and their staffs can access CTSU at www.ctsu.org, where protocol-specific and general educational materials can be easily downloaded. "CTSU has made it possible for investigators to participate in trials that are best for their patients, even if the trial is not being led by their group. This is helping to shorten the time needed to complete some important protocols, such as CALGB C40101, ECOG 3200 and NCIC-CTG MA.27. The original vision of the CTSU is starting to be realized," said Steve Riordan, CTSU project director.

New Deputy Directors Announced at All-Hands Meeting
Speaking at his second "all-hands" meeting since becoming NCI director, Dr. Andrew C. von Eschenbach announced the establishment of four new deputy director positions that "will be arrayed across the realm of the discovery, development, and delivery continuum," and "help to organize and orchestrate the entire NCI portfolio."

Dr. Anna Barker, currently deputy director for Strategic Scientific Initiatives, has been named deputy director for Advanced Technologies and Strategic Partnerships. Dr. Mark Clanton will serve as deputy director for Cancer Care and Delivery Systems. Negotiations are ongoing with candidates for the position of deputy director for Integrative Biology and Molecular Oncology as well as deputy director for Translational and Clinical Sciences.

NCI at AAAS
Attendees at the 2004 annual meeting of the American Association for the Advancement of Science can visit NCI in the meeting's exhibit hall from Feb. 13 through 16. Attendees will be able to learn about NCI, its research resources, and opportunities for training.